Determine patient demographic and clinical characteristics at baseline clinical trials

Efficacy and Safety of Dalbavancin As Suppressive Therapy

This study looks at how well and how safely a medicine called Dalbavancin (DAL) works as a long-term treatment for serious infections. It focuses on people who have already received DAL for infections between 2019 and 2024.